Navigation Links
Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM)

- Safe Driving Pledge Unveiled as Part of Nationwide Awareness Campaign -

KENILWORTH, N.J., March 18 /PRNewswire-FirstCall/ -- This spring allergy season, Schering-Plough (NYSE: SGP), maker of the non-drowsy allergy medicine, CLARITIN, is continuing its partnership with allergy sufferer and NASCAR driver Carl Edwards to encourage safe driving practices.

To view the Multimedia News Release, go to:

"Drowsy driving is dangerous so I'm participating in the CLARITIN Clear to Drive campaign because I want to make sure people know to check medicine labels for warnings about drowsiness before getting behind the wheel," said Edwards. "As someone who races cars for a living, I can't risk taking an allergy medicine that might make me drowsy. Now I use new CLARITIN(R) Liqui-Gels(R) because it relieves my worst allergy symptoms and it's the only non-drowsy option in an easy-to-swallow liquid-filled capsule."

For the second year in a row, Edwards is the voice of the CLARITIN Clear to Drive(SM) campaign, which aims to prevent drowsy driving and encourages people to stay alert while on the road. This year's campaign asks consumers to take an online pledge and commit to safe driving practices by visiting For every pledge made, the makers of CLARITIN will donate $1 (up to $30,000) to the National Safety Council.

"As a leader in promoting safe driving practices, the National Safety Council supports the CLARITIN Clear to Drive(SM) campaign and its effort to prevent drowsy driving," said Janet Froetscher, president & chief executive of the National Safety Council. "Considering crashes are the number-one cause of accidental death in the U.S., it's important to pay close attention to our driving habits and take the necessary steps to stay alert on the road."

To learn more about drowsy driving and to take the Clear to Drive pledge, visit


All CLARITIN(R) brand products are available without a prescription, including: CLARITIN(R) Tablets, a once-daily, full prescription strength, non-drowsy formulation; CLARITIN(R) RediTabs(R) Tablets, a novel once-daily formulation in a quickly dissolving tablet for ages 6 and older; CLARITIN(R) Liqui-Gels(R), a once-daily formulation in an easy-to-swallow liquid-filled capsule; CLARITIN-D(R) 24-hour and 12-hour Extended Release Tablets, with the decongestant pseudoephedrine, now located behind the counter; CHILDREN'S CLARITIN(R) Syrup, a liquid formulation for children ages 2 and older in grape and fruit flavors; and CHILDREN'S CLARITIN(R) Grape Chewables, a chewable tablet for children ages 2 and older.

CLARITIN(R) is the No. 1 physician-recommended and pediatrician-recommended non-drowsy over-the-counter allergy brand. The CLARITIN(R) Rx-to-OTC switch in 2002 was the largest switch ever-and the first and only for a non-drowsy antihistamine. For more information on allergies and treatment, visit

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is

SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Video: Record Number of Patients Seek Laser Treatments to Take Light-Years Off Their Faces
2. Video: New Report Card: Nations Mental Health Care System
3. Video: Injectable-Grade Filler, Now Without the Injections
4. Video: Avon Commits Over $1.75 Million for New Partnerships to End Violence Against Women
5. Video: Novalar Announces the Launch of OraVerse(TM) the First Dental Anesthesia Reversal Agent
6. Video: CVS/pharmacy and National Council on Aging Kick Off Medication Management Program for Seniors
7. Video: Facing the Facts - What You Need to Know About Facial Plastic Surgery
8. Video: Majority of Americans Over 45 Experience Joint Pain and Believe it will Affect Their Future Quality of Life
9. Video: The MDS Foundation Says Published Data Confirms VIDAZA(R) Significantly Extends Survival in Patients with the Malignant Condition MDS
10. Video: On 100th Anniversary, Mental Health America Declares Its Time for Mental Health
11. Video: Ear Infections Spark Online Conversations Among Concerned Parents
Post Your Comments:
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: